Fresh analysis suggests that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds far faster than those who end traditional lifestyle plans.
Findings released in a major medical journal demonstrates that while overweight people can lose a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing these drugs should be aware of the risk of quick weight regain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to pre-treatment mass within about a year and a half.
Analyzing Approaches
The research, which looked at 37 of trials involving over 9,000 of participants, contrasted the effects of these new drugs with conventional dieting.
Scientists note that individuals who shed pounds through diet and exercise generally see a more gradual weight regain—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Doctors propose the way of the jabs explains the amplified regain.
These medications mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production might result in the body to produce less of its own natural hormone, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication leads to appetite is unsuppressed, making excessive eating far more likely."
An Ongoing Disease?
Medical guidelines suggest the jabs for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals contend that, given the likelihood of weight regain, the treatment is often life-long.
This perspective is supported by drug manufacturers, who note that the results "underscore the persistent character of excess weight," similar to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the medication describe a powerful resurgence of hunger.
"I experienced a trigger flipping and you're instantly starving," described an individual.
This challenge is exacerbated if patients have not developed lasting dietary or behavioural modifications during therapy.
Growing Adoption
Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is greater among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while the jabs are powerful agents for shedding pounds, they are not a magic cure and maintained weight loss likely depends on integrated lifestyle support.